Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Capital Area Research LLC

Neither a doctor nor a teaching hospital

Research payments

$10,354,615

620 payments

Through program year 2025, Capital Area Research LLC is reported as receiving $10,354,615 in research payments, across 620 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,907,607 190
2024 Research $1,528,892 66
2023 Research $1,621,789 78
2022 Research $1,940,891 81
2021 Research $1,337,196 88
2020 Research $1,042,250 68
2019 Research $975,991 49

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $4,221,191 100 payments
  2. Pfizer Inc. $3,019,419 174 payments
  3. Amgen Inc. $2,055,276 55 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $362,545 19 payments
  5. Baxter Healthcare $162,758 6 payments
  6. Eisai Inc. $126,922 2 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $100,028 48 payments
  8. Boehringer Ingelheim Pharma GmbH & Co.KG $91,256 8 payments
  9. Boehringer Ingelheim International GmbH $89,904 122 payments
  10. Esperion Therapeutics, Inc. $53,186 78 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $1,757,866 54 payments
  2. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $999,314 10 payments
  3. A Study of Tirzepatide (Ly3298176) Once A Week Versus Insulin Glargine Once A Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk $598,388 12 payments
  4. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $500,624 35 payments
  5. A Phase 2A Randomized Doubleblind Sponsoropen Placebocontrolled Parallel Group Doseranging Study of Pf07976016 to Assess Safety and Efficacy in Adult Participants With Obesity $401,901 23 payments
  6. FOURIER OLE (Ph 4) $387,798 7 payments
  7. A Phase 2 Study of Once-Daily Ly3502970 Compared With Placebo in Participants Who Have Obesity Or Are Overweight With Weight-Related Comorbidities $383,717 4 payments
  8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $358,310 4 payments
  9. A Lowinterventional Prospective Longitudinal Cohort Study to Collect Digital Functional Assessments and Evaluate Symptoms in Study Participants With Chronic Heart Failure $317,722 41 payments
  10. 20170625_Vesalius - CV $288,909 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record